GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rigel Pharmaceuticals Inc (STU:RI2A) » Definitions » Cyclically Adjusted Price-to-FCF

Rigel Pharmaceuticals (STU:RI2A) Cyclically Adjusted Price-to-FCF : (As of Jun. 22, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Rigel Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Rigel Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Rigel Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rigel Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Rigel Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Rigel Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Rigel Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Rigel Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rigel Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Rigel Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Rigel Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Rigel Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Rigel Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.027/131.7762*131.7762
=-0.027

Current CPI (Mar. 2024) = 131.7762.

Rigel Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.168 100.560 -0.220
201409 -0.162 100.428 -0.213
201412 -0.140 99.070 -0.186
201503 0.188 99.621 0.249
201506 -0.184 100.684 -0.241
201509 -0.098 100.392 -0.129
201512 -0.144 99.792 -0.190
201603 -0.226 100.470 -0.296
201606 -0.180 101.688 -0.233
201609 -0.213 101.861 -0.276
201612 -0.119 101.863 -0.154
201703 -0.171 102.862 -0.219
201706 -0.142 103.349 -0.181
201709 -0.119 104.136 -0.151
201712 -0.116 104.011 -0.147
201803 -0.130 105.290 -0.163
201806 -0.147 106.317 -0.182
201809 -0.104 106.507 -0.129
201812 0.061 105.998 0.076
201903 -0.005 107.251 -0.006
201906 -0.089 108.070 -0.109
201909 -0.081 108.329 -0.099
201912 -0.055 108.420 -0.067
202003 -0.020 108.902 -0.024
202006 -0.074 108.767 -0.090
202009 -0.099 109.815 -0.119
202012 -0.078 109.897 -0.094
202103 -0.096 111.754 -0.113
202106 0.267 114.631 0.307
202109 -0.052 115.734 -0.059
202112 -0.099 117.630 -0.111
202203 -0.137 121.301 -0.149
202206 -0.071 125.017 -0.075
202209 -0.079 125.227 -0.083
202212 -0.120 125.222 -0.126
202303 -0.103 127.348 -0.107
202306 0.031 128.729 0.032
202309 -0.007 129.860 -0.007
202312 -0.033 129.419 -0.034
202403 -0.027 131.776 -0.027

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Rigel Pharmaceuticals  (STU:RI2A) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Rigel Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Rigel Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Rigel Pharmaceuticals (STU:RI2A) Business Description

Traded in Other Exchanges
Address
611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Rigel Pharmaceuticals (STU:RI2A) Headlines

No Headlines